Literature DB >> 22426996

Study of the regulation of the inotropic response to 5-HT4 receptor activation via phosphodiesterases and its cross-talk with C-type natriuretic peptide in porcine left atrium.

S Weninger1, J H De Maeyer, R A Lefebvre.   

Abstract

We studied how 5-HT(4) receptor-mediated inotropic responses are regulated at the level of cAMP in porcine left atrium. We used selective phosphodiesterase (PDE) inhibitors to assess which PDE subtypes are responsible for the fade with time of inotropic responses to 5-HT(4) receptor activation with 5-HT and the 5-HT(4) receptor agonist prucalopride. A possible cross-talk via PDEs between cGMP and 5-HT(4) receptor-induced cAMP signalling was evaluated. Electrically paced left atrial pectinate muscles from young male pigs (15-25 kg) were studied in vitro. Simultaneous inhibition of PDE3 plus PDE4 subtypes was necessary to increase the amplitude and completely prevent the fade of the inotropic response to 5-HT and prucalopride. When responses to 5-HT or prucalopride had faded 1 h after addition, the nonspecific PDE-inhibitor IBMX still fully recovered inotropic responses. Stimulation of particulate guanylyl cyclase, together with PDE2 and PDE4 inhibition, delayed the fade of the response to 5-HT, while stimulation of soluble guanylyl cyclase independently of PDEs accelerated the fade of the response to 5-HT. In conclusion, both PDE3 and PDE4 subtypes are responsible for the suppression and the fade of the inotropic response to 5-HT and prucalopride. Signalling through the 5-HT(4) receptor remains fully active for at least 90 min with PDEs continuously regulating the response. cGMP levels, elevated by activation of particulate guanylyl cyclase under PDE2 inhibition, can indirectly enhance 5-HT(4) receptor-mediated signalling, at least when also PDE4 is inhibited, presumably through inhibition of PDE3. Elevation of cGMP generated by soluble guanylyl cyclase attenuates responses to 5-HT independently of PDEs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22426996     DOI: 10.1007/s00210-012-0746-y

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  37 in total

Review 1.  Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3).

Authors:  E Degerman; P Belfrage; V C Manganiello
Journal:  J Biol Chem       Date:  1997-03-14       Impact factor: 5.157

Review 2.  Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels.

Authors:  Rodolphe Fischmeister; Liliana Castro; Aniella Abi-Gerges; Francesca Rochais; Grégoire Vandecasteele
Journal:  Comp Biochem Physiol A Mol Integr Physiol       Date:  2005-05-31       Impact factor: 2.320

Review 3.  Regulation of cardiac contractile function by troponin I phosphorylation.

Authors:  Joanne Layland; R John Solaro; Ajay M Shah
Journal:  Cardiovasc Res       Date:  2005-04-01       Impact factor: 10.787

4.  Mediation of 5-hydroxytryptamine-induced tachycardia in the pig by the putative 5-HT4 receptor.

Authors:  C M Villalón; M O den Boer; J P Heiligers; P R Saxena
Journal:  Br J Pharmacol       Date:  1990-08       Impact factor: 8.739

Review 5.  Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases.

Authors:  Rodolphe Fischmeister; Liliana R V Castro; Aniella Abi-Gerges; Francesca Rochais; Jonas Jurevicius; Jérôme Leroy; Grégoire Vandecasteele
Journal:  Circ Res       Date:  2006-10-13       Impact factor: 17.367

6.  5-Hydroxytryptamine increases contractile force in porcine right atrium but not in left ventricle.

Authors:  R G Schoemaker; X Y Du; W A Bax; P R Saxena
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-11       Impact factor: 3.000

7.  A 5-HT4-like receptor in human left atrium.

Authors:  L Sanders; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-04       Impact factor: 3.000

8.  Increased effects of C-type natriuretic peptide on contractility and calcium regulation in murine hearts overexpressing cyclic GMP-dependent protein kinase I.

Authors:  Kai C Wollert; Sevdalina Yurukova; Ana Kilic; Frank Begrow; Beate Fiedler; Stepan Gambaryan; Ulrich Walter; Suzanne M Lohmann; Michaela Kuhn
Journal:  Br J Pharmacol       Date:  2003-11-10       Impact factor: 8.739

9.  Phosphorylation of C-protein, troponin I and phospholamban in isolated rabbit hearts.

Authors:  J L Garvey; E G Kranias; R J Solaro
Journal:  Biochem J       Date:  1988-02-01       Impact factor: 3.857

10.  Ontogenic changes of the control by phosphodiesterase-3 and -4 of 5-HT responses in porcine heart and relevance to human atrial 5-HT(4) receptors.

Authors:  Alejandro Galindo-Tovar; Maria Luisa Vargas; Elisa Escudero; Alberto J Kaumann
Journal:  Br J Pharmacol       Date:  2009-01-19       Impact factor: 8.739

View more
  7 in total

1.  Influence of phosphodiesterases and cGMP on cAMP generation and on phosphorylation of phospholamban and troponin I by 5-HT4 receptor activation in porcine left atrium.

Authors:  Sabine Weninger; Joris H De Maeyer; Romain A Lefebvre
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-03       Impact factor: 3.000

2.  Which phosphodiesterase can decrease cardiac effects of 5-HT4 receptor activation in transgenic mice?

Authors:  Joachim Neumann; Benedikt Käufler; Ulrich Gergs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-04-24       Impact factor: 3.000

3.  Identification of small molecule NPR-B antagonists by high throughput screening--potential use in heart failure.

Authors:  Trond Bach; Stine Bergholtz; Jon Riise; Eirik Qvigstad; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-12-03       Impact factor: 3.000

4.  Differential regulation of C-type natriuretic peptide-induced cGMP and functional responses by PDE2 and PDE3 in failing myocardium.

Authors:  Lise Román Moltzau; Silja Meier; Jan Magnus Aronsen; Faraz Afzal; Ivar Sjaastad; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy; Eirik Qvigstad
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-01-15       Impact factor: 3.000

5.  Cardiac PDEs and crosstalk between cAMP and cGMP signalling pathways in the regulation of contractility.

Authors:  Finn Olav Levy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-05-07       Impact factor: 3.000

6.  cAMP Catalyzing Phosphodiesterases Control Cholinergic Muscular Activity But Their Inhibition Does Not Enhance 5-HT4 Receptor-Mediated Facilitation of Cholinergic Contractions in the Murine Gastrointestinal Tract.

Authors:  Vicky Pauwelyn; Romain A Lefebvre
Journal:  Front Pharmacol       Date:  2018-03-08       Impact factor: 5.810

Review 7.  Phosphodiesterases and Compartmentation of cAMP and cGMP Signaling in Regulation of Cardiac Contractility in Normal and Failing Hearts.

Authors:  Gaia Calamera; Lise Román Moltzau; Finn Olav Levy; Kjetil Wessel Andressen
Journal:  Int J Mol Sci       Date:  2022-02-15       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.